A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation

This phase I study was designed to examine the maximum tolerated dose (MTD), the dose-limiting toxicities (DLTs), the recommended dose (RD) for phase II, and the pharmacokinetics of NK105, a new polymeric micelle carrier system for paclitaxel (PTX). NK105 was administered as a 1-h intravenous infusi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of cancer 2007-07, Vol.97 (2), p.170-176
Hauptverfasser:	Hamaguchi, T, Kato, K, Yasui, H, Morizane, C, Ikeda, M, Ueno, H, Muro, K, Yamada, Y, Okusaka, T, Shirao, K, Shimada, Y, Nakahama, H, Matsumura, Y
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Agents, Phytogenic - adverse effects Antineoplastic Agents, Phytogenic - pharmacokinetics Antineoplastic Agents, Phytogenic - therapeutic use Biological and medical sciences Biomedical and Life Sciences Biomedicine Cancer Research Clinical Study Digestive System Neoplasms - diagnostic imaging Digestive System Neoplasms - drug therapy Drug dosages Drug Resistance Epidemiology Ethanol FDA approval Female Hematology Humans Male Maximum Tolerated Dose Medical research Medical sciences Micelles Middle Aged Molecular Medicine Nanoparticles Nanoparticles - adverse effects Nanoparticles - therapeutic use Neutropenia Oncology Paclitaxel - adverse effects Paclitaxel - analogs & derivatives Paclitaxel - pharmacokinetics Paclitaxel - therapeutic use Patients Permeability Pharmacokinetics Polyethylene glycol Tomography, X-Ray Computed Toxicity Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!